The oncogenic tyrosine kinase activity of KIT and PDGFRA was significantly inhibited by imatinib, resulting in obviously improved prognosis of GIST patients harboring oncogenic mutations in KIT/PDGFRA. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.